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ABSTRACT 
The unfavorable prognosis of malignant gliomas can also be explained by the incomplete 
knowledge of their molecular pathways. Studies regarding the regulatory process of 
apoptosis in glioblastoma (GBM), the most common malignant glioma, are few, and better 
knowledge of the expression of pro and anti-apoptotic proteins could collaborate with 
the development of new treatments founded on molecular basis. The objective of this 
study was to evaluate by immunohistochemistry the expression of caspase-3 and Bcl-2 
in 30 samples of GBMs. The expression of caspase-3 (mean 17.67%) was lower than Bcl-2 
(mean 30.92%), a statistically significant result (p<0.0001), suggesting low apoptotic activity 
in these tumors. Other studies of proteins related to the intrinsic and extrinsic pathway of 
apoptosis are required to provide additional information of this mechanism in GBMs.
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RESUMO 
O prognóstico desfavorável dos gliomas malignos também pode ser explicado pelo pouco 
conhecimento dos seus mecanismos moleculares. Estudos relacionados à regulação do 
processo de apoptose em glioblastoma (GBM), o glioma maligno mais comum, são poucos, 
e o melhor conhecimento da expressão de proteínas pró e anti-apoptóticas poderia 
colaborar com o desenvolvimento de novos tratamentos fundamentados sobre a base 
molecular. O objetivo deste estudo foi avaliar por imunohistoquímica, a expressão de 
caspase-3 e Bcl-2 em 30 amostras de GBM. A expressão de caspase-3 (média de 17,67%) 
foi menor que a de Bcl-2 (média de 30,92%), com resultado estatisticamente significante 
(p<0.0001), sugerindo menor atividade apoptótica nestes tumores. Outros estudos 
envolvendo proteínas relacionadas à via extrínseca e intrínseca da apoptose são necessários 
para fornecer informações complementares deste mecanismo em GBMs. 
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Astrocytic tumors are the most fre-
quent forms of gliomas (65 to 70%). Ac-
cording to World Health Organization 
(WHO), these tumors are classified based 
on histological and clinical criteria in: pilo-
cytic astrocytoma (Grade I), and diffuse-
ly infiltrative astrocytomas, diffuse astro-
cytoma (Grade II), the anaplastic astrocy-
toma (Grade III) and glioblastoma (Grade 
IV), the most malignant variety1,2.
Glioblastoma (GBM) represents 29% of 
all brain tumors and 69% of astrocytic and 
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oligodendroglial tumors. Despite surgery, chemotherapy 
and radiotherapy, most of GBMs have poor prognosis. 
The survival time is less than one year and the five year 
survival rate is less than 10%3,4. 
Apoptosis is a programmed cell death with significant 
role in development and homeostasis of multicellular or-
ganisms. Most of the biological processes during apopto-
sis are caused by cysteine proteases that are part of a large 
family of proteins known as caspases5. These proteins are 
homologous, and their enzymatic activity is divided into 
two classes: initiators and effectors6.
The apoptotic response is mediated through two path-
ways: extrinsic and intrinsic, depending on the origin of 
the stimulus of death. The extrinsic pathway is initiated 
by the addition of extracellular ligands of death recep-
tors on the cell surface death6, while the intrinsic or mi-
tochondrial pathway is triggered by the translocation of 
mitochondrial apoptotic Bcl-2 family members, such as 
Bax, Bad and Bim. The apoptotic pathways are still poor-
ly known in GBMs7. The anti-apoptotic members of this 
family include BCL2 and BCLX preserve the integrity of 
mitochondria and prevent the release of Cytochrome C 
in the presence of apoptotic stimuli. The BCL2 gene en-
codes a protein of 26 kDa membrane-associated, which 
shows the program inhibit cell death and thus promote 
cell survival8,9. The caspases constitute a large family of 
proteins homologous with each other, enzymatic activity 
and that are activated in cells marked for death by apop-
tosis. They are the central components of apoptotic re-
sponse and are generally divided into two classes: initiator 
and the effector caspases, wich includes caspase-36.
Studies related to the regulatory process of apoptosis 
in GBMs are few, and greater knowledge of the expres-
sion of these proteins is necessary to provide additional 
information to collaborate on new treatments planed on 
molecular basis in the near future
The aim of this study was to evaluate, by immuno-
histochemistry, the protein expression of caspase-3 and 
Bcl-2 in GBMs.
METHOD
This study comprised 30 samples of GBMs (13 wom-
en and 17 men), from 2002 to 2007, and was performed 
in the Faculty of Medicine of Ribeirão Preto, University 
of São Paulo. The study was approved by the Ethics Com-
mittee of the FMRP-USP.
The samples embedded in paraffin were cut in Reich-
ert Jung 2040 microtome with 3μm thick, deparaffinized 
and hydrated. The sections were incubated with 3% H2O2 
and Pierce solution to block endogenous peroxidase and 
biotin, respectively. Subsequently the antigen retrieval 
was performed in buffer 1 mM EDTA, pH 8.0 for cas-
pase-3 and buffer 10 mM Tris Base, 1 mM EDTA, pH 9.0 
for Bcl-2. The samples were incubated with primary an-
tibodies against isoformas caspase-3 cleaved - (CPP32) 
monoclonal - Novocastra® in dilution of 1:200 (synthe-
sized as an inactive 32 kD proenzyme and is processed 
during apoptosis to its active), and Bcl-2 - (NCL-BCL-2-
486) monoclonal - Novocastra® in dilution 1:200 and with 
biotin-conjugated secondary anti-rabbit antibody (1:1000; 
Vector Laboratories Inc., Burlingame, CA) and strepta-
vidin-conjugated peroxidase (Vecstatin Abc kit, Vector 
Laboratories Inc.). Color was developed by the addition 
of DAB (Sigma Chemical, St. Louis, MO). To evaluate the 
background reaction, procedures were also perfomed in 
sections incubated only with the secondary antibodies 
(indirect technique) or in the absence antibodies (direct 
technique). The number with positive staining for cas-
pase-3 and Bcl-2 isoforms was measured by using a cam-
era (Axio Cam, Zeiss, Germany) and the program Axiovi-
sion 4.6 (Zeiss, Germany), in an increase of 400×.
For the analysis of protein expression related to apop-
tosis (caspase-3 and Bcl-2), two fields in areas with higher 
concentration of positive cells (“hot spots” areas) were se-
lected in each slide. This methodology was used because 
the protein marking was not always observed diffusely in 
the samples studied. In order to evaluate the staining in-
tensity, we used a semi-quantitative method (+ to +++), 
and also calculated the percentage of stained (positive) 
cells in relation to the number of total cells. 
Statistical analysis was performed using the Mann-
Whitney test from the GraphPad Prism Version 4.00 
for Windows (GraphPad Software, San Diego Califor-
nia USA). The p values<0.05 were considered statistical-
ly significant.
RESULTS 
Protein expression of caspase-3 antibody
A semiquantitative analysis of caspase-3 showed that 
in most samples (22 - 73.33%) the protein expression was 
low (+), intermediate (++) in 5 samples (16.66%), and high 
(+++) in one sample (3.33%) and negative in two samples. 
The percentage of positive cells to caspase-3 ranged from 
7.36% to 59.52% (Table and Fig 1).
Protein expression of Bcl-2 antibody
A semiquantitative analysis of Bcl-2 showed that the 
protein expression in most of the samples (18 - 60%) 
was intermediate (++), low (+) in 10 samples (33.33%) 
and high (+++) in two samples (6.66%). The percentage 
of positive cells for Bcl-2 ranged from 16.64% to 56.92% 
(Table and Fig 2). 
The expression of the two proteins were different, the 
staining for caspase-3 antibody (mean 17.67± 2.043) was 
lower than Bcl-2 antibody (mean 30.92±1.954) (Fig 3), 
p<0.0001.
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Table. Protein expression of caspase-3 and Bcl-2 in GBM represented by the percentage of positive cells and semi-quantitative analysis.
Samples
Bcl-2
% of positive cells
Bcl-2 
Semi-quantitative analysis
Caspase-3 
% of positive cells
Caspase-3
Semi-quantitative analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Mean
44.38%
34.83%
30.93%
33.06%
19.66%
17.19%
16.64%
52.36%
31.97%
20.53%
35.88%
29.33%
31.15%
18.09%
22.47%
39.12%
16.73%
29.65%
37.22%
30.14%
18.85%
45.26%
23.48%
27.10%
56.92%
38.81%
44.72%
21.63%
26.70%
32.95%
30.92%
++
++
++
++
+
+
+
+++
++
+
++
++
++
+
+
++
+
++
++
++
+
++
+
++
+++
++
++
+
++
++
18.02%
–
–
15.23%
15.08%
37.02%
59.52%
7.36%
25.11%
14.08%
11.45%
12.73%
14.55%
21.28%
24.48%
14.74%
26.39%
15.38%
20.17%
19.05%
25.15%
9.12%
24.76%
12.04%
8.78%
11.49%
12.02%
25.72%
18.13%
11.46%
17.67%
+
–
–
+
+
++
+++
+
++
+
+
+
+
+
+
+
++
+
+
+
++
+
+
+
+
+
+
++
+
+
Fig 1. Photomicrography of caspase-3 expression in GBM. Positive cells are indicated by arrows (400×).
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DISCUSSION
Recent studies provide evidences that, contrary to the 
traditional view, most spontaneous cell deaths in malig-
nant gliomas are due to apoptosis rather than necrosis10.
Dysregulation of apoptotic mechanisms plays impor-
tant role in the pathogenesis and progression of various 
cancers and also poor responses of tumors to therapeu-
tic interventions. Highly invasive cancer cells are protect-
ed from apoptosis by up regulation of various anti-apop-
totic molecules including B cell lymphoma-2 (Bcl-2) pro-
tein. Over expression of Bcl-2 provides a survival advan-
tage to cancer cells in response to a wide range of apoptot-
ic stimuli through inhibition of mitochondrial cytochrome 
c release11,12. Consistent with these findings, our results 
showed high protein expression of Bcl-2 (average of 30.92% 
of positive cells in 30 samples), providing molecular evi-
dence that the protein Bcl-2 can reduce cell death in GBM.
George, Banik and Ray13 studied the action of an an-
ti-neoplastic drug, taxol, that binds b-tubulin, to prevent 
tumor cell division, promoting cell death. In this study, 
Bcl-2 expression was inactivated using siRNA during tax-
ol treatment, in order to evaluate apoptosis in two GBM 
cell lines, U138MG and U251MG. Increased apoptosis 
occurred after treatment with taxol alone, Bcl-2 siRNA 
alone, and both agents together. Western blotting showed 
increased levels of Bax, tBid (pro-apoptotic members of 
the Bcl-2 family) and also active caspases that promote 
apoptosis. In summary, the result showed that chemother-
apy could be more efficient if Bcl-2 could be inactivated.
Molecular events associated with apoptosis, includ-
ing effectors caspases, such as caspase-3, has been shown 
to be present in the U87 GBM xenografts14,15. Zarnescu 
et al.16 investigated the immunohistochemical expression 
of caspase-3, 9 and Bax in intracranial U87 GBM xeno-
graft. The study showed that GBM xenografts contain 
positive cells for the three proteins. A previous immuno-
histochemical study indicated expression of caspase-3 in 
more than 50% of tumor cells and caspase-9 in more than 
10% tumor cells from high-grade anaplastic astrocytomas 
Fig 2. Photomicrography of Bcl-2 expression in GBM. Positive cells are indicated by arrows (400×).
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Fig 3. Mean and standard deviation of the percentage of positive 
cells to caspase-3 and Bcl-2 in GBMs. 
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and GBMs17. Moreover, RT-PCR experiments and West-
ern blot analysis have shown over expression of pro-apop-
totic Bax and up regulation of caspase-3 and caspase-9 in 
GBM multiforme derived from patients who had not re-
ceived previously radiotherapy or chemotherapy18. 
Recent studies offer a new perspective on presence of 
caspases, mainly caspase-3, in the tumor cells19,20. Gdynia 
et al.20 reported that in the absence of cellular stress, ac-
tive caspases are constitutively present in GBM cells and 
promote their motility. Moderate active caspase-3 lev-
els are found in human GBM samples, freshly isolated 
GBM cells, and long-term cultured glioma cell lines. The 
amount of active caspase-3 and other caspases is not suf-
ficient to induce apoptotic cell death, but it contributes 
substantially to the motility of GBM cells. Thus, the find-
ings of Zarnescu et al.16 reasonably speculate that the 
presence of immunostaining for caspase-3 in U87 GBM 
xenografts might be correlated both with migration in 
the host brain and apoptosis. In our study we observed 
lower protein expression of caspase-3 (average of 17.67% 
of positive cells in 30 samples) compared to the expres-
sion of Bcl-2, suggesting that anti-apoptotic mechanisms 
in these tumors are higher than the pro-apoptotics, al-
though we do not have studied other effectors and initi-
ators proteins related to intrinsic and extrinsic pathways 
of apoptosis. Nevertheless, seven samples showed high-
er expression of caspase-3 compared to Bcl-2, as 59.52% 
of positive cells in the sample seven. These results agree 
with those obtained by Zarnescu et al.16 and as described, 
can be explained by the action of caspase-3 is involved in 
the process of cell migration. 
The evaluation of the behavior of other apoptotic pro-
teins and anti-apoptotic related to their intrinsic and ex-
trinsic pathway are necessary for better understanding 
the cellular mechanism in GBM. Furthermore, cellular 
mechanisms such as angiogenesis, cell proliferation and 
cell adhesion, among others, as well as proteins related to 
the control of the cell cycle, may be involved as mecha-
nisms in parallel characterization of the behavior of this 
type of tumor and may also explain the lower apoptotic 
index in our work. 
In conclusion, this study presents evidence that apop-
tosis is inhibited in GBMs. Further analysis are need to 
be done to evaluate the therapeutic potential of apoptotic 
and anti-apoptotic proteins in the treatment of GBM.
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